Overview

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Glycine
Pioglitazone